Share Name Share Symbol Market Type Share ISIN Share Description
4basebio Uk Societas LSE:4BB London Ordinary Share GB00BLD8ZL39 ORD EUR1.00
  Price Change % Change Share Price Shares Traded Last Trade
  -5.00 -1.23% 400.00 6,225 10:47:00
Bid Price Offer Price High Price Low Price Open Price
390.00 410.00 405.00 400.00 405.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.46 -0.72 -8.00 49
Last Trade Time Trade Type Trade Size Trade Price Currency
16:24:25 O 900 400.00 GBX

4basebio Uk Societas (4BB) Latest News

More 4basebio Uk Societas News
4basebio Uk Societas Investors    4basebio Uk Societas Takeover Rumours

4basebio Uk Societas (4BB) Discussions and Chat

4basebio Uk Societas Forums and Chat

Date Time Title Posts
09/6/202107:484BaseBio - Innovation in Gene Synthesis and Delivery47

Add a New Thread

4basebio Uk Societas (4BB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all 4basebio Uk Societas trades in real-time

4basebio Uk Societas (4BB) Top Chat Posts

4basebio Uk Societas Daily Update: 4basebio Uk Societas is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker 4BB. The last closing price for 4basebio Uk Societas was 405p.
4basebio Uk Societas has a 4 week average price of 370p and a 12 week average price of 315p.
The 1 year high share price is 687.50p while the 1 year low share price is currently 147.50p.
There are currently 12,317,473 shares in issue and the average daily traded volume is 11,585 shares. The market capitalisation of 4basebio Uk Societas is £49,269,892.
pob69: Finncap view with a target price under review (current MC £44.3m) "...Based on comparisons to more mature peers and discounting back to present day, it is possible to envisage the value of 4bb’s technology rising to c.£75- 100m in the near term, once key milestones such as GMP-grade DNA are met"
multibagger: Zurg The Indestructible For someone who has followed and invested in the company since 2003 confirms my assertion that you are too emotionally invested in it and intimately associated with it. If it is such a stellar company, why have you not invested more given you have had 18 years to do so and you say you have just a small stake ? Was there no liquidity ever ? Don't get carried away that 4BB is the only player in synthetic DNA - there are other companies which are much bigger. Touchlight for one - by a distance. 4BB are simply not in the ballpark compared to MXCT - so don't get carried away with your idolisation of 4BB and what the management have achieved so far. Each investor has different investment nthresholds that make their time worthwhile - the negligible number of shares available may be fine for smaller traders/investors, but these numbers don't move the needle for me. I can't be bothered buying 10 or 15 shares at a time. 3x or 4x of a tiny number of shares are not worth my time or effort - and I certainly won't be wasting my time doing due diligence on this - as I said initially this was just an impulse buy as a starter position. I find that my starter position is a stalled position, as there is no liquidity. You continue banging on the drum, singing their praises and keep buying and good luck to you and all holders - it may be the ideal share for you and many others, but not for me. We have to agree to disagree :) I will post my opinions and views as I see fit, the fact that you may not agree with it, or vehemently disagree is something for you to handle/cope. The filter button will save you a lot of angst. Good luck !
hydrus: It is extremely illiquid and that is annoying particularly with the large spread. That said the illiquidity has zero impact on the likely success of the underlying business so I'm relaxed about it. The business won't be a busted flush due to share illiquidity Multi - it's all about whether their innovations work. Big unknown but the management have a great track record. I'd rather they focussed on the business rather than worry about the share price and liquidity
zurg the indestructible: "So far, 4BB is a listing experiment in Frankfurt that did not play out as hoped and I get the impression that it was time to test the water across the Channel." Sygnis merged with Expedeon and 4 years later half the IP was sold to ABCAM for 120m euro's. Now the cash has been split from the IP. I suggest you do some proper due diligence on this company before you post the above. You have a rather high opinion of yourself "4BB is at a much earlier stage of its evolution and the BoD here have a lot to learn still - more importantly they need to be willing to learn !!" I suggest you look at the track record of the company since the merger of Sygnis and Expedeon in 2016 and also do a bit of research into the major shareholders and the man behind them. Sparta AG Delphi Deutsche Balaton Sygnis merged with Expedeon and 4 years later half the IP was sold to ABCAM for 120m euro's. Now the cash has been split from the IP. You are trashing the company in a fit of pique that you cannot pick up the amount of stock you want.
zurg the indestructible: Multibagger If the company increased liquidity by raising cash that is not needed it would undoubtedly be by Institutions and not necessarily result in more shares in circulation. as for your ascertation that the share price would be 3x or 4x higher, so what, all it would mean is that the share price has got ahead of itself. What this share needs is news which results in the price rising and tempting holders to sell. The majority of the free float is in German hands and I don't think it would take too much of a rise to tempt them to sell. I am sorry to dissappoint you but I am not a director or management or even an employee but just a shareholder from the initial start up in 2003 and I only have a small holding. I do not understand what you mean by a re run of the Frankfurt listing, that was a merger with Sygnis which was already on the Frankfurt market and there was plenty of liquidity there. If you think the share price should be 3x then why are you not slowly accumulating at these levels?
multibagger: Many thanks for sharing relevant excerpts pob69...much appreciated ! I have been invested in MXCT for about a year now, so have seen my initial outlay multiplied over 5 fold so far and I have been adding regularly to take it to a decent holding. 4BB is at a much earlier stage of its evolution and the BoD here have a lot to learn still - more importantly they need to be willing to learn !! I have interacted with the CE of MXCT, so my impression of MXCT is that, it is led from a much more astute, market savvy and a visionary kind of mindset apart from cutting edge scientific IP. Doug has been in the market for a couple of decades, so he is able to showcase what the market looks for from an investment perspective. So far, 4BB is a listing experiment in Frankfurt that did not play out as hoped and I get the impression that it was time to test the water across the Channel. No thought appears to have been given about liquidity issues or whether there are actually shares to be traded. To be taken seriously by the wider market, the liquidity issue needs to change sharpish. Case in point, today being the busiest trading day so far on AIM since its listing as far as I can recall and on the back of a Broker note comparing 4BB to MXCT it musters about 22,027 shares traded in total. Total equity is 12,317,473 shares. So on what should have been a good trading day 0.17% changes hands !! That is really taking the Mick !! So 4BB could be a busted flush in due course if liquidity does not position about wanting to get out has not changed as it does not meet my investment criteria from a position size point of view (as of now). Which is saying a fair bit as I hold decent positions in relatively ill liquid shares like ARC and TRT. Good luck all !
multibagger: I gather a Finncap broker note has been released which may explain a bit of life in the share today. 4BB company is in the right space and at the right time, market sentiment for cutting edge biotech is red hot. However, the lack of liquidity is asphyxiating this share and BoD don't seem to get this. If liquidity issues are ironed out on the UK market, through raising funds (even though funds may not be immediately necessary), then paradoxically I see this trading at 4x or 5x, the share price we are at now. So one of those rare instances when equity dilution and fund raising will actually benefit the share price, contrary to what the BOD think. Time for the major share holders on the BoD to relax and not try to hold on far too tightly to their shares. It is counterproductive. Contrarian thinking one could argue, but could be transformative to unleash the potential of this share. I am sure that the senior people of 4BB from a scientific background, are sharp enough to understand how markets work or how investors/traders think. Or else this UK AIM listing will be a re-run of the Frankfurt all over again.....and then will they consider listing in Paris or Oslo I wonder ?
zurg the indestructible: Multibagger The reason why the company listed on AIM was to seek a valuation on the Technology. Whilst on the Frankfurt exchange the company was aleays trading at a discount to the cash from the Abcam sale. The company has no need of cash and as you know the shares are tightly held. It would be wrong to raise money that the company didn't need and dilute shareholders in the process. As for mangement, look at the way the CEO has transformed the company since 2016 when Sygnis merged with Expedeon. What more are you looking for than a CEO who protects shareholders from dilution, has a large shareholding and a proven track record. I understand you are dissappointed not to have picked up shares more easily but 5k is £20k and if you are patient you will be able to pick up more shares as I suspect German holders will see the price settle and decide to cash out. When you look at the prices Pharma have paid (billions) for other companies in this area I reckon you would be mad to sell up.
multibagger: Good morning nimbo1 and all :) I see 4BB as an "acquisition play" by big pharma for its evolving and developing technology. I don't expect 4BB to make profits (almost never)- in fact I expect recurrent losses and high cash burn. Can't be more honest than that. However, they won't be short of funding as there are deep pockets to fund such ground breaking tech in the current scheme of things. However, I think that they are onto something which could end up very interesting with wide utility in applications - it is literally a "blink" moment like I had with MXCT. Synthetic DNA (hairpin DNA or hpDNA) IP is a key driver IMHO and if this 4BB process can be scaled for quantity, produced faster and validated for quality, then vaccine development from largely plasmid based DNA will change dramatically. Vaccines are here to stay and the issues/constraints with bioreactors are becoming more well known...and therefore valuations of companies which can create a new paradigm shift like 4BB can detach from reality....just as TESLA,ITM and Bitcoin can, anything is possible in this bubble. Just can't buy in quantity at this time which is frustrating. I intend to keeping adding in the times when it is available. My risk appetite can be high, but I am very comfortable with my investing style - it works for me ! Good luck all :)
tomps2: 4basebio #4BB CEO presentation. Good overview of the business and their vision. hxxps://
4basebio Uk Societas share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
4basebio U..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210612 23:55:41